Exploring Lipoprotein-Associated Phospholipase A2 Levels in Iraqi Patients with Stable Angina: Insights from Coronary Angiography Diagnosis

Stable angina is a prevalent heart disease which can be defined as a clinical syndrome of stable coronary artery disease (CAD) that refers to the presence of myocardial ischemia. Lipoprotein-associated Phospholipase A2 (Lp-PLA2) is an important biomarker of atherosclerosis progression through pro-inflammatory and anti-inflammatory effects. Objective: The aim was to detect the role of Lp-PLA2 in the diagnosis of patients with stable angina and normal left ventricular ejection fraction (LVEF). Patients and methods: The study design was a case-control study. 90 males and females (age 40-76 years) who were presented with chest pain were enrolled in the study, all were subjected to echocardiography, ECG and coronary angiography by the cardiologist. Besides, patient’s questionnaire and biochemical analysis were also used. According to the angiography, they were divided into two groups: 60 patients and 30 as a control group. Levels of Lp-PLA2, total cholesterol, triglycerides (TG), high density lipoprotein-Cholesterol (HDL-C), very low density lipoprotein-Cholesterol (VLDL-C) and low density lipoprotein-Cholesterol (LDL-C) in serum were assessed. The biplane M mode method was used to measure left ventricular ejection fraction (LVEF). Result: It was detected that Lp-PLA2 serum levels were significantly higher in the patients than in the control, (P≤0.01). ROC analysis showed that Lp-PLA2 had specificity of 100% and sensitivity 100%. Conclusion: Measurement of Lp-PLA2 can be applied as an excellent biomarker in the diagnosis of patients with stable angina and normal LV ejection fraction.